Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus to tacrolimus + sirolimus conversion to improve fourth-dose SARS-CoV-2 vaccine seroconversion in unresponsive solid organ transplant recipients
2022-000617-13Phase 4Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Mar 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus, tacrolimus, mycophenolate mofetil and mycophenolic acid in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Positive humoral immune response after fourth mRNA SARS-CoV-2 vaccine dose. Started Mar 2022; status: completed.
02
Drugs
sirolimustacrolimusmycophenolate mofetilmycophenolic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000617-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000617-13.